Markets:

Overview

News

Currencies

International

Treasuries

Virios Therapeutics, Inc. - Common Stock (NQ:VIRI)

0.1550 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Virios Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2022 ↗

September 20, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 20, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 20, 2022

Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!

Via InvestorPlace

Virios Therapeutics Shares Tank After Failing Fibromyalgia Study ↗

September 19, 2022

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket ↗

September 20, 2022

Gainers

Via Benzinga

Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗

September 20, 2022

Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.

Via Benzinga

Virios Therapeutics, Inc. Announces Pricing of Public Offering

September 19, 2022

From Virios Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 19, 2022

Gainers Reshape Lifesciences (NASDAQ:RSLS) stock increased by 10.1% to $0.39 during Monday's after-market session. The company's market cap stands at $1.3 million.

Via Benzinga

Virios Therapeutics, Inc. Announces Proposed Public Offering

September 19, 2022

From Virios Therapeutics, Inc.

Via Business Wire

US Markets Turn Higher As Dow Jumps Over 100 Points ↗

September 19, 2022

U.S. stocks traded higher in volatile trading toward the end of trading, with the Dow Jones gaining more than 100 points on Monday.

Via Benzinga

Dow, S&P 500 Drop In Volatile Trading Ahead Of Fed's Rate Decision ↗

September 19, 2022

U.S. stocks traded lower in volatile trading toward the end of trading, with the Dow Jones dropping around 40 points on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 19, 2022

Via Benzinga

Analyzing Virios Therapeutics's Short Interest ↗

September 19, 2022

Virios Therapeutics's (NASDAQ:VIRI) short percent of float has risen 6.58% since its last report. The company recently reported that it has 53 thousand shares sold short, which is...

Via Benzinga

Why Is Virios Therapeutics (VIRI) Stock Down 71% Today? ↗

September 19, 2022

Virios Therapeutics (VIRI) stock is falling hard on Monday after revealing results from its Phase 2b Study of IMC-1 in Fibromyalgia.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Monday ↗

September 19, 2022

On Monday, 429 stocks made new 52-week lows.

Via Benzinga

Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗

September 19, 2022

Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.

Via Benzinga

US Stocks Open Lower; Housing Market Index Drops In September ↗

September 19, 2022

U.S. stocks traded lower this morning, after recording losses in the previous week.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 19, 2022

Via Benzinga

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

September 19, 2022

From Virios Therapeutics, Inc. (VIRI)

Via Business Wire

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 15, 2022

Via Benzinga

Virios Therapeutics Commences Mid-Stage Long-COVID Study ↗

August 15, 2022

Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).

Via Benzinga

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

August 15, 2022

From Virios Therapeutics, Inc. (VIRI)

Via Business Wire

This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday ↗

August 17, 2022

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.

Via Benzinga

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 11, 2022

From Virios Therapeutics, Inc.

Via Business Wire

Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference

August 10, 2022

From Virios Therapeutics, Inc.

Via Business Wire

Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

August 09, 2022

Via ACN Newswire

Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

August 08, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022

August 04, 2022

From Virios Therapeutics, Inc.

Via Business Wire

Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment

July 26, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.